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1CHAPTER I
INTRODUCTION
Inflammation is considered a host defense mechanism that is employed to initiate
the healing process of damaged tissues (Slauson, et ai, 1990). The study of the
inflammatory process over the centuries has given us the five cardinal signs of
inflammation: heat, redness, pain, swelling, and loss of function (Lee, et ai, 1992;
Slauson, et ai, 1990). The release of cytokines, the activation and migration of
leukocytes, and the production of antibodies are some of the components of the
inflammatory process that interact in a complex manner to produce the signs listed above.
Eicosanoids are important in the chronic inflammatory process of canine osteoarthritis.
The products of arachidonic acid are metabolized by either the cyclooxygenase pathway
or the lipoxygenase pathway (Ringler, et aI, 1997; Slauson, et aI, 1990). The
cyclooxygenase pathway produces prostaglandins, prostacyclin, and thromboxane
necessary for vasodilatation, increased vascular permeability and platelet aggregation
(Higgins, et ai, 1984; Tizard, 1996). The lipoxygenase pathway produces the
leukotrienes which serve to activate and stimulate migration of leukocytes (Lewis, et ai,
1990). The leukotrienes also stimulate vasoconstriction of smooth muscle and increase
vascular permeability at the site of inflammation. (Lewis, et aI, 1990).
Corticosteroids are drugs which have the ability to block the release of
arachidonic acid and the subsequent release of its products (Barragry, 1994). The many
adverse effects of corticosteroids make their utilization too costly over a prolonged period
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of time (Plumb, 1999). The non-steroidal anti-inflammatory drugs (NSAIDs) have fewer
adverse effects compared to the corticosteroids, but are effective only in inhibiting the
cyclooxygenase pathway (Tizard, 1996~ Campbell, et ai, 1996). The novel dual
cyclooxygenasellipoxygenase inhibitor, tepoxalin, appears to be the best drug to treat
chronic inflammatory conditions in that it is able to inhibit eicosanoid production without
adverse effects (Wallace, et aI, 1991,1993). The active acidic metabolite that is produced
is believed to inhibit the cyclooxygenase pathway while the parent drug, tepoxalin,
inhibits the lipoxygenase pathway (Waldman, et ai, 1996). One study has looked at the
effects of a fasting diet in the absorption of tepoxalin, but no other type of diet has been
investigated (Waldman, et ai, 1996). Therefore, the objectives of this study were to
detennine the phannacokinetics, in particular the ahsorption, of tepoxalin in the canine
and to study the effect of dietary fat on drug bioavailability.
3CHAPTERIl
LITERATURE REVIEW
Pathophysiology of Inflammation
The study of inflammation dates back to the first century when the Roman,
Cornelius Celsus, first characterized it as calor, rubor, tumor, et dolor (heat, redness,
swelling, and pain) (Lee, et ai, 1992). A fifth sign, loss of function, was later added by
Rudo1fVirchow in the 1800's (Slauson, et ai, 1990). These five signs are known today as
the "cardinal signs" of inflammation.
Inflammation is the reaction of the tissue of an organism to an irritant, which can
be infectious, chemical, physical, immunologic, or radiant in nature (Slauson, et ai, 1990;
Lee, et ai, 1992). The majority of complex organisms utilize the inflammatory response
(Slauson, et ai, 1990). If living organisms did not have an adequate inflammatory
response to fight disease, they would not be here today (Slauson, et ai, 1990).
The inflammatory response incorporates many different components, which III
tum interact independently and with one another to create the signs seen with this
response. Some processes which are initiated are chemotactic stimuli for cellular
response, lysozomal enzyme release, antibody production, and the activation of the
complement, coagulation, fibrinolytic, and kinin pathways (Lee, et ai, 1992). The type of
reaction, whether it is acute or chronic, can influence the participants in the inflammatory
4process (Tizard, 1996). Also, the type of irritant detennines which compon nts ar
produced and how they interact (Tizard, 1996).
The four original classical signs of inflammation are what describe an acute
response (Lee, et ai, 1992). When a cell is damaged, it releases chemotactic and
vasoactive factors into the blood stream where neutrophils and eosinophils become the
first responders to the chemotactic signals of damaged tissues (Tizard, 1996). They
phagocytize and destroy foreign material and in tum release more chemotactic factors to
signal other specific leukocytes to the site of tissue damage (Tizard, 1996). The
vasoactive factors which are released help stimulate vasodilatation and increase vascular
permeability by acting on the smooth muscle of the blood vessels within the damaged
area (Tizard, 1996). These vasoactive mediators can originate from the damaged tissue,
the responding leukocytes, or the intermediate products of the inflammatory process.
The most common signs seen with chronic inflammation are persistent pain and
swelling of the affected area, without redness or heat, which can lead to a loss of function
(Lee, et aI, 1992). Also, the composition of the cells in a chronic inflammatory response
is different from an acute response. Monocytes are attracted to the area and are activated
to macrophages, which in tum phagocytize any foreign material and help destroy
damaged tissue (Tizard, 1996). The macrophages also release interleukin-l (IL-1), which
stimulates the formation of fibrin and collagen and allows the healing process to begin
(Tizard, 1996).
The etiology of the inflammatory response determines how well the organism can
respond. If the offending agent is rapidly and completely removed, then the healing
process is uneventful (Tizard, 1996). If inorganic substances or certain bacterial or fungal
5infections persist, then the organism fonns a granuloma and tries to wall it off from the
surrounding healthy tissue (Tizard, 1996). The nonnal inflammatory response of an
organism can also lead to excessive scarring and granulation tissue fonnation which in
turn can lead to joint immobility (Slauson, et ai, 1990).
The degenerative joint disease, osteoarthritis, is considered a phenomenon of
aging (Rosenberg, 1999; Schiller, et ai, 1999). Although the majority of human cases are
55 years old or older, 5% of cases are younger individuals who have had an injury to a
joint, a congenital deformity of a joint, or an underlying systemic disease (Rosenberg,
1999). Osteoarthritis can afflict a number of people in any age category and is the
number one cause of arthritis in the United States. (Schiller, et af, 1999).
There does not appear to be any initiating cause of osteoarthritis (except in young
people) and it can be localized or generalized (Rosenberg, 1999). The disease is
characterized by the narrowing of the joint space, increasing subchondral bone thickness
with cysts, and the fonnation of osteophytes (Schiller, et ai, 1999). These events are the
result of the destruction of articular cartilage by chondrocytes releasing IL-l and tissue
necrosis factor alpha (TNF-a) (Rosenberg, 1999; Schiller, et af, 1999). It has also been
discovered that the prostaglandins and interleukin-6 (IL-6) degrade the cartilage matrix
which can cause joint pain following activity (Schiller, et ai, 1999; Rosenberg, et ai,
1999). Since the pathway for the production of prostaglandins is known, this is the area
being extensively researched for the development of pain relievers for osteoarthritis and
similar conditions.
6The Role of Eicosanoids in lnflammation
Prostaglandins, along with leukotrienes and thromboxane, are called eicosanoids
and are the metabolites of the arachidonic acid pathway (Ringler, 1997). Arachidonic
acid is a 20-carbon polyunsaturated fatty acid derived from the conversion ofIinoleic acid
or directly as a dietary source (Collins, 1999). It is found esterified to phospholipids of
cell membranes, commonly as phosphatidylcholine (Slauson, et ai, 1990; Collins, 1999).
In order to produce the metabolites, arachidonic acid must first be liberated from the cell
membrane by the disruption of the intact cell membrane and subsequent release of
arachidonic acid, or by an antigenic or mediator stimulus (Slauson, et ai, 1990; Ringler,
1997).
The antigenic or mediator ligand binds to a specific membrane-bound receptor,
which comes into contact with a membrane-bound protein called G-protein that is then
activated (Collins, 1999). The activated G-protein in turn causes the hydrolysis of
phosphatidylinositol-4, 5-bisphosphate (PIP2) to inositol-I, 4, 5-triphosphate (IP3) and
diacylglycerol (DAG) (Collins, 1999). IP3 goes to the endoplasmic reticulum and
stimulates the release of calcium ions into the cell (Collins, 1999). The increase in
cytosolic calcium activates phospholipase A2, which hydrolyzes arachidonic acid and
releases it from the cell membrane where it is then metabolized hy one of two pathways
(Ringler 1997; Slauson, et ai, 1990).
The pathways are named for the two enzyme systems which metabolize
arachidonic acid: cyclooxygenases and Iipoxygenases. The first enzyme in the
cyclooxygenase pathway consists of two isofonns: cyclooxygenase-l (COX-I) and
7cyclooxygenase-2 (COX-2) (Campbell, et ai, 1996). The fonn expressed depends upon
the cell and the type of stimulus (Campbell, et ai, 1996). This enzyme converts
arachidonic acid to prostaglandin G2 (PGG2) and then converts PGG2 to prostaglandin H2
(PGH2), both ofwhich are unstable (Campbell, et ai, 1996). Various enzymes then act on
PGH2 to produce the eicosanoids seen in the inflammatory response. Prostacyclin
synthase converts PGH2 to prostacyclin (PGI2) (Campbell, et ai, 1996). Isomerases
convert PGH2 to prostaglandin E2 (PGE2), prostaglandin F2ex (PGF2ex), and prostaglandin
D2 (PGD2) (Campbell, et ai, 1996). Thromboxane synthase forms thromboxane A2
(TXA2) from PGH2 (Campbell, et ai, 1996).
As soon as the cyclooxygenase pathway is activated, so is the lipoxygenase
pathway (Higgins, et aI, 1984). Two different enzymes begin this pathway. The 12-
lipoxygenase enzyme converts arachidonic acid to a 12-hydroperoxyeicosatetraenoic acid
(HPETE), which is then converted to a 12-hydroeicosatetraenoic acid (HETE) (Higgins,
et ai, 1984). The 5-lipoxygenase enzyme acts on arachidonic acid to form 5-HPETE
which is either converted to 5-HETE by various enzymes or to leukotriene AJ. (LTAJ.) by
LTA synthase (Higgins, et aI, 1984). LTA hydrolase converts LTAJ. to leukotriene B4
(LTB4) (Higgins, et aI, 1984). Leukotriene C4 synthase can also convert LTAJ. to
leukotriene C4 (LTC4), which subsequently fOnTIS leukotriene D4 (LTD4), leukotriene E4
(LTE4), and leukotriene F4 (LTF4) (Higgins, et aI, 1984). These two pathways are
illustrated in Figure 1.
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Figure 1. The Generation of arachidonic acid metabolites and their roles in inflammation
(Collins, 1999).
9Each of the metabolites produced by the cyclooxygenase and the lipoxygenase
pathways have a role in the inflammatory response and their action depends upon the
stimulus and the tissue in which they exist (Campbell, el ai, 1996). The functions of the
following eicosanoids will be discussed: PGb, PGE2, PGF2a, TXA2, and LTB4.
Vasodilatation and increased vascular penneability is induced by PGh and PGE2
(Higgins, et ai, 1984). These two eicosanoids are also responsible tor the enhancement of
pain induced by seratonin and bradykinin (Lee, et at, 1992). Platelet aggregation is
inhibited by PGI2 and PGF2a while it is promoted by PGE2 and TXA2 (Tizard, 1996).
PGF2a and TXA2 also stimulate smooth muscle contraction and vasoconstriction (Tizard,
1996). LTB4 is chemotactic for neutrophils and helps them stick to endothelial cells in
the affected area (Lewis, et aI, 1990). Many of these mediators have various responses
depending on their site of action, but all of them contribute to the signs seen with acute
inflammation (heat, redness, swelling, and pain). Because of this, it is difficult to develop
one drug that can relieve all of these signs.
The Effects of Corticosteroids on Inflammation
Steroids have been called the "silver bullets" when it comes to treating the
symptoms of inflammation. They are able to suppress the redness, heat, and swelling of
an acute inflammatory response and also reduce any fever if present (Davis, et ai, 1992).
Glucocorticoids act at the level of arachidonic acid release from the cell membrane by
inhibiting phospholipase A2 (PLA2) activity (Barragry, 1994).
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Corticosteroids can bind with a specific glucocorticosteroid receptor (GR) on the
cell membrane or diffuse through the membrane and bind with a GR in the cytoplasm of
the cell (Ferguson, et ai, 1995). GR's within the cell are inactive and are bound to heat-
shock proteins (HSP) -70 and -90, and immunophilin (Schimmer, et ai, 1996). When the
steroid binds, the proteins are released and the GR translocates the steroid to the nucleus
(Ferguson, et aI, 1995). In the nucleus, the steroid-receptor complex binds to
glucocorticoid response elements (GRE's) present on certain genes of the DNA and alters
their products (Davis, et ai, 1992). The new proteins that result serve to enhance or
inhibit specific cellular functions (Davis, et aI, 1992).
One such protein that is produced is lipocortin (Ferguson, et ai, 1995). It serves to
inhibit PLAzactivity and both the cyclooxygenase and lipoxygenase pathways (Ferguson,
et aI, 1995). The production of prostaglandins, leukotrienes, and thromboxane is
inhibited and their activity on various cells can no longer occur in the inflammatory
response.
The corticosteroids can also have direct effects on the cells of the inflammatory
response. They decrease the number of lymphocytes in the circulation by sequestering
them in lymphoid tissue and bone marrow (Winkelstein, 1992). Monocytes, eosinophils,
and basophils are redistributed while neutrophils are rapidly released from the bone
marrow into the circulation, but their functions are inhibited at the site of inflammation
(Winkelstein, 1992). Interleukin-l synthesis from monocytes is inhibited and monocytes
cannot be activated to macrophages (Winkelstein, 1992). These are just a few of the
many changes that occur in response to inflammation.
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The structures of the corticosteroids lend themselves to easy modification to
enhance their rate of absorption by various routes (Davis, et ai, 1992). Corticosteroids
can be absorbed from the gastrointestinal (GI) tract, through the skin, or given
intravenously or intramuscularly depending on how they are formulated (Davis, et ai,
1992). Glucocorticoids are metabolized by the liver and excreted by the kidneys (Davis,
et ai, 1992).
Along with their ability to inhibit many characteristics of inflammation,
corticosteroids also have many adverse effects on the organism. These effects are
common when the drugs are given over an extended period of time. Plumb (1999) lists
the adverse effects seen in dogs in his Veterinary Drug Handbook as: "dull, dry hair coat,
weight gain, panting, vomiting, diarrhea, elevated liver enzymes, pancreatitis, Gl
ulceration, lipidemias, activation or worsening of diabetes mellitus, muscle wasting and
behavioral changes". Polyuria, polydipsia, and polyphagia are the more frequent signs
that dog owners report seeing (Plumb, 1999). Another problem with corticosteroids is
that they have to be tapered off slowly so the pituitary-hypothalamic pathway of the
animal, which produces steroids in the body, can resume its normal production of
glucocorticosteroids. (Plumb, 1999). If this does not happen, the excess steroid injected
into the dog will suppress the production of adrenocorticotrophic hormone (ACTH),
which in tum leads to the deficiency of cortisol secretion from the adrenal glands and
hypoadrenocorticism (Plumb, 1999).
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The Effects of on-Steroidal Anti-Inflammatory Drugs on Inflammation
Other drugs, such as the NSAIDs, have been developed that do not have as many
adverse effects as corticosteroids yet give similar results. The NSAIDs can be divided
into two groups: the prostaglandin synthetase inhibitors (PSIs) and the non-prostaglandin
synthetase inhibitors (non-PSIs) (Lee, et aI, 1992).
The PSIs consist of those drugs which are derived from carboxylic acid or enolic
acid compounds and are considered weak organic acids (Lee, et aI, 1992). The PSIs act
by inhibiting the cyclooxygenase enzyme and, therefore, the production of prostaglandins
and thromboxane (Inse1, 1996). The non-PSIs, on the other hand, are grouped according
to their effects on the symptoms expressed and, therefore, are umelated compounds (Lee,
et ai, 1992). Some examples are gold (an antirheumatoid arthritis agent) and allopurinol
(an antigout agent) (Lee, et ai, 1992).
The mechanism of action of aspirin, the most popular NSAID and PSI, is to
acetylate serine 530 of COX-1 or serine 516 of COX-2, which results in an irreversible
inhibition of the cyclooxygenase enzyme (Insel, 1996). The duration of the effect of
aspirin on the enzyme is determined by how quickly more cyclooxygenase enzyme is
produced (Insel, 1996). Even though NSAIDs like aspirin can provide relief to the
symptoms of inflammation, they do nothing to inhibit the pathologic process of the
disease itself (Ferguson, et aI, 1995).
Many NSAIDs which are indicated for the treatment of osteoarthritis or a
musculoskeletal disorder are given orally and are readily absorbed from the stomach and
small intestine (Lee, et aI, 1992). Flunixin meglumine is one NSAID which is injectable
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(Lee, et ai, 1992). The different formulations of SAlDs allow for a choic of routes of
administration and the ability to control possible adverse reactions based on the animal's
state of health.
The adverse reactions seen with NSAIDs typically involve the gastrointestinal
system (Insel, 1996). Irritation of the stomach or small intestine can lead to vomiting and
diarrhea with possible ulceration and blood loss (Insel, 1996). This can be alleviated by
giving the drug in a buffered form or reducing the dosage or duration (Insel, 1996).
Another adverse effect is on the hemopoietic system. With the inhibition of
thromboxane. platelet function is ceased and this leads to an increase in the bleeding time
(Insel, 1996). This can cause serious problems if the animal has an extensive laceration.
Depending on the drug, hepatic and renal adverse effects can also occur (Insel,
1996). Hypersensitivity reactions have occurred with aspirin or its derivatives, but this is
less common (Plumb, 1999).
The majority of these adverse effects occur because the NSAID has to be given at
a high dose over an extended period of time (Plumb, 1999). Decreasing the dose or
shortening the duration will lower the efficacy of the drug. Newer drugs are being
developed that have the desirable action of corticosteroids with fewer adverse effects like
the non-steroidal anti-inflammatory drugs.
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The Potential Role of Tepoxalin in the Treatment of Inflammation
Tepoxalin is a novel dual cyclooxygenasef1ipoxygenase (CO /LO) inhibitor which
has been studied extensively at the R. W. Johnson Phannaceutical Research Institute
(Argentieri, et ai, 1994). Although another dual inhibitor, BW755C, was studied
extensively at the research institute, tepoxalin was found to be 3.5 times more potent
(Anderson, et ai, 1990). Tepoxalin inhibits both cytokine production and leukocyte
activation and migration seen in the inflammatory response. It has the potential to be a
potent inhibitor of inflammation in many aspects of osteoarthritis, without the side effects
seen with the NSAIDs
Two functional groups included in the drug structure have been shown to have
their effects in the cyc100xygenase pathway. The cyclooxygenase activity of
prostaglandin-H synthase-1 (PGHS I) is believed to be inhibited by the pyrazole group
while the peroxidation of PGG2 to PGH2 is blocked by the hydroxamic acid group, which
is an iron chelator (Tam, et ai, 1995). Tepoxalin is a noncompetitive inhibitor, although
the exact binding site on PGHS 1 is unknown (Tam, et ai, 1995). Tam, et ai, have studied
tepoxalin and believe it binds close to tyrosine 384 of PGHS I and alters its conformation
to elicit the hydrolysis of arachidonic acid while the hydroxamic acid of tepoxalin
chelates the heme group of tyrosine 385 and inactivates peroxidase (1995).
The 5-lipoxygenase (5-LO) pathway is thought to be inhibited by the binding of
tepoxalin to the 5-LO activating protein to prevent its activation, but the specifics of this
interaction have not been worked out (Rainsford, et ai, 1996). The mechanism of action
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tepoxalin preventing the decay and subsequent release of hcB (which inactivates NFKB
and keeps it in the cytoplasm) from NFxB (Kazmi, et aI, 1995; Beg, et aI, 1993).
One of the effects of this inactivation of NFxB is the inhibition of leukocytes.
The cell adhesion molecules CD62E, CD11 b/CD] 8, and CD 106 are inhibited through the
inactivation of NFxB while intracellular adhesion molecule-l (lCAM-1) expression is
blocked through the inhibition of IFN-y by tepoxalin (Lee, et aI, 1996; Zhou, et aI, 1996).
These molecules allow for the adhesion of leukocytes to vessel walls. The migration of
neutrophils is blocked by the inhibition of Mac-l and E-selectin indirectly through NFK.B
(Zhou, et aI, 1996).
Tepoxalin is rapidly metabolized within the body. It is subjected to the first-pass
effect whereby the parent drug is inactivated when it passes through the liver by hepatic
enzymes (Benet, et aI, 1996). In this way, significant amounts of the drug will not appear
in the general circulation (Benet, et aI, 1996). This leads to the formation of an active
acidic metabolite that has been observed in many individual studies (Knight, et aI, 1996;
Depre, et ai, 1996; Waldman, et ai, 1996). The plasma levels of the metabolite compared
to the active drug rise much higher and remain high for 24 hours while the active drug
shows a rapid decline in this time period (Knight, et ai, 1996; Depre, el aI, 1996;
Waldman, et ai, 1996). This metabolite was shown to inhibit cyclooxygenase while the
parent drug, tepoxalin, inhibited Iipoxygenase in a time-dependent and dose-dependent
fashion (Waldman, et ai, 1996).
Although the metabolism of the drug has been studied, the factors affecting the
absorption of the drug have not been as extensively studied. One experiment looked at
the effect of diet on absorption of the drug from the gastrointestinal tract. Waldman, et
17
aI, concluded that tepoxalin was readily absorbed after oral administration of 20 healthy
male volunteers in the fasting state (1996). 0 studies have been done to date to
determine how diet affects absorption in dogs. More experiments need to be conducted
to investigate the pharmacokinetics of tepoxalin. The fat content of the diet may have a
more profound effect on the absorption of tepoxalin from the gastrointestinal tract than a
fasting state.
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CHAPTERID
EXPERIME TAL OBJECTNES
The hypothesis upon which this research was based is that tepoxalin exhibits a
pharrnacokinetic disposition suitable for oral therapy in dogs and that dietary fat content
does not adversely affect oral bioavailability. This hypothesis was tested by conducting a
pharrnacokinetic study designed to compare the oral bioavailability of tepoxalin and its
pharmacologically active acid metabolite in fasted dogs and dogs fed either a low-fat or
high-fat commercial diet. The specific objectives were:
(1) to detennine the oral bioavailability of a novel rapid-dissolution formu lation of
tepoxalin; and
(2) to investigate the effects of fasting and dietary fat content on bioavailability of
tepoxalin and its acid metabolite.
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CHAPTER IV
MATERIAL AND METHODS
Animals
The animals used in this study were purpose-bred Beagles purchased from a
breeding facility. The three males and three females were one-year-old and weighed
approximately 7.5 - 9.7 kg. Upon arrival, the dogs were given a physical examination by
a veterinarian. The veterinarian's assessment, along with the CBC and vaccination history
that accompanied the animals, concluded that all were healthy, heartworm negative, and
had no underlying medical problems. Fenbendazole was administered as a prophylactic
anthelmintic. The dogs were housed in separate dog runs for the duration of the study.
Animal use was approved by the OSU Institutional Animal Care and Use Committee
(Protocol No. 689).
Experimental Design
The dogs were administered tepoxalin intravenously (IV) or orally (PO) with 3
different diets. The treatments were given in such a way that one male and one female
received the same treatment and diet per treatment period. The fasted (Fast) diet
consisted of no food ]2 hours prior to drug administration until 4 hours after drug
administration. The low fat (Lfat) diet consisted of dry feed (Canine Maintenance
...
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Science Diet, 15.4% fat as a proportion of dry matter) fed 30 minutes prior to drug
administration. The high fat (Hfat) diet was a canned feed (Canine/Feline aid
Prescription Diet 28.7% fat as a proportion of dry matter) fed 30 minutes prior to drug
administration. These diets were only given on the days Tepoxalin was administered.
The dogs received Canine Maintenance Science Diet dry feed for the other days of the
study.
The experimental design is described in Table I:
TABLE 1 - Assignment of treatments to individual animals
Dog Identification
Treatment #3308- #3309- Male#3310- Male #3311- #3312- #3313-
Period Male Female Female Female
I PO/Fast POILfat PO/Hfat POlHfat PO/Lfat PO/Fast
2 PO/Lfat PO/Hfat PO/Fast POfFast PO/Hfat POILfat
3 PO/Hfat PO/Fast POILfat PO/Lfat PO/Fast PO/Hfat
4 IV IV IV IV IV IV
Ten days between treatment periods were allowed as washout periods. The
complete eliminations of tepoxalin and its metabolite were confirmed be collecting blood
10 days after the first dose of tepoxalin was administered and assaying it for the drug and
its metabolite.
,
21
Drug Administration and Sample Collection
For oral administration, Schering Plough Animal Health Research supplied
tepoxalin as Tepoxalin Zydis 50 mg tablets. The tablets were administered by placing on
the dorsum of the tongue, closing the mouth, and then stroking the throat for 10 seconds
to stimulate the swallowing reflex. The dosage given was 10 mglkg. This was
accomplished by cutting the tablets when necessary using a sharp scalpel blade applied
along the diameter of the tablet to give approximately two equal pieces to dose to the
closest 25 mg increment. Doses administered are listed in Table 2:
TABLE 2 - Doses administered to individual dogs.
DogID Starting weigh POfFast POlLfat PO/Hfat IV (m1)
(kg)
#3308 8.2 1 + 1/2 tabs 1 + 1/2 tabs 2 tabs 2.0
#3309 8.2 2 tabs 1 + 1/2 tabs 2 tabs 2.0
#3310 9.7 2 tabs 2 tabs 2 tabs 2.2
#3311 7.6 1 + 1/2 tabs 2 tabs I + 1/2 tabs 1.9
#3312 7.9 1 + 1/2 tabs 1 + 1/2 tabs I + 1/2 tabs 1.6
#3313 7.5 I + 1/2 tabs 1 + 1/2 tabs 1 + 1/2 tabs 1.6
For intravenous administration, Schering Plough Animal Health Research
supplied the tepoxalin as Tepoxalin Injectable solution 50 mg/mt. The calculated IV dose
was identical to the PO dose used in the previous treatment period and was administered
as a bolus dose via a catheter into the cephalic vein over a period of 60 seconds.
Blood samples were collected into heparinized tubes by cephalic venipuncture
before drug administration and at 0.25, 0.5, I, 2, 3, 4, 6, 8, 12, 16, 24, 32, and 48 hours
...
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after PO administration and at 0.083, 0.17, 0.33, 1,2,3,4,6 8 12, 16,24, 32, and 48
hours after IV administration.
Drug Assay
The blood samples were centrifuged and the plasma was harvested within 24
hours of sample collection. The plasma was then refrigerated at 4 C until it was assayed
within 72 hours of collecting it. The plasma samples were then subjected to high
performance liquid chromatography using a modification of a procedure developed by the
R. W. Johnson Pharmaceutical Research Institute to determine the concentrations of
tepoxalin and its active acidic metabolite.
The drug and its metabolite were first extracted from the plasma sample. A glass
test tube was used to combine 0.5 ml of plasma, 20 ul of internal standard (a derivative of
tepoxalin), 1 M phosphate buffer (pH = 6), and 5 ml of methyl-t-butyl ether. The tube
was capped, vortexed for 30 seconds and then centrifuged until the organic layer was
separated from the aqueous layer. The organic layer was removed, placed in another
glass test tube, and then evaporated under a N2 stream in a water bath. The precipitate
was dissolved in 200 ul of mobile phase, which was a mixture of 43% buffer (1.1 g 1-
octane, sulfonic acid, sodium salt dissolved in 970 ml deionized water and 20 ml 99%
triethylamine, pH = 5), 20% methanol, 20 % tetrahydrofuran, and 17% acetonitrile.
Concentration standards were prepared using plasma from untreated dogs and
adding the correct amounts of tepoxalin and its acid metabolite prepared in methanol to
generate 0, 0.125, 0.25, 0.5, 1.0, 2.0, and 4.0 uglml for oral dosing and 0, 0.125, 0.25, 0.5,
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1.0, 2.0, 4.0, 8.0, and 16 ug/ml for rv dosing. The standards were subjected to the same
extraction procedure as described earlier and were made fresh every day.
All extracted samples were filtered through 0.45 urn filters and 50 ul aliquots were
then injected into a high performance liquid chromatography system consisting of a
gradient programmer (Model 2360, Isco, Inc), pump (Model 2350, lsco, Inc), variable
wavelength absorbance detector (Model V4, Isco, Inc) set at 254 nrn, and an integrator
(Model SP 4290, Spectra-Physics). A 150 x 4.6 mm Cl8 column (Nucleosil 5um,
Phenomenex) was also used. The flow rate of the mobile phase was 0.9 mVrninute and
all chromatography was done at room temperature.
The relationships between standard concentration and ratios of tepoxalin or acid
metabolite and internal standard peak heights were best described using second-order
polynomial equations (R2>0.9). The limit of quantitation (LOQ) of the assay was 0.125
ug/ml. The limit of detection (LOD) was defined by the peak threshold setting of the
integrator: peak heights that were not recorded because they were lower than this
threshold were considered to be below the LOD. All estimates of intra-assay precision
were within acceptable limits (:S5.57%) at the 0.25 uglml and at 2 ug/ml concentration
levels. Accuracy was :S12.40% at the 0.25 uglml and at 2 uglml concentration levels,
except for at 0.25 uglml tepoxalin (19.08%). Acceptable limits for both the intra-assay
precision and the accuracy are <15%. Samples frozen at 20 C for 2 weeks showed no
significant loss of stability.
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Data Analysis
The pharmacokinetic values, area under the curve (AUC) area under the first
moment curve (AUMC), mean residence time (MRT), time to peak concentration (Tmax)'
and peak concentration (Cmax) were calculated using a model-independent approach with
the use of a computer program (Bourne, 1989). Areas under the tepoxalin and acid
metabolite concentration-time curves were calculated from time-zero to the last sampling
time, using the trapezoidal method. Terminal rates of elimination, necessary for
calculation of elimination half-lives, were estimated by fitting concentration-time data to
biexponential equations using a computer program for iterative least-squares regression
analysis (Brown and Manno, 1978). Oral bioavailability of tepoxalin was estimated by
calculating the individual ratios of areas under the PO and IV curves.
The effects of diet on the bioavailability of tepoxalin and acid metabolite were
tested by comparing the fraction of drug absorbed (F) (for tepoxalin) and Cmax and Tmax
(for tepoxalin and acid metabolite) using the general linear model and separation of
means by Scheffe's test. F values were log-transformed prior to analysis. Means were
considered significant at the P <0.05 level.
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CHAPTER V
RESULTS
Concentrations of tepoxalin and acid metabolite in plasma after oral or
intravenous administration of tepoxalin are presented in Tables 3 - 6 and in Figures 2 &
3. The concentration of tepoxalin declined rapidly in the first 6 hours after intravenous
administration when a dose of 10 mg/kg was given. It then demonstrated a more gradual
decline over the next 10 hours and was still detected in the plasma 16 hours after
administration. These results suggest that tepoxalin is rapidly metabolized after
absorption, which is consistent with the observation that concentrations of acid
metabolite were consistently higher than corresponding concentrations of the parent
tepoxalin, indicating that tepoxalin is subject to a substantial first-pass effect.
Pharmacokinetic parameters describing bioavailability of tepoxalin and its acid
metabolite are listed in Tables 7 & 8. Feeding significantly increased Cmax values for
tepoxalin. Although similar trends were suspected for F values for tepoxalin and Cmax
values for the acid metabolite, the variabilities of these estimates were too high for
significance to be demonstrated. Nevertheless, it is clear that if feeding affects oral
absorption of tepoxalin administered to patients, it is likely to improve bioavailability.
Closer examination of individual concentration-time profiles revealed considerable
variation in bioavailabiJity that was probably related to both oral absorption of tepoxalin
and conversion of parent tepoxalin to acid metabolite. Whether dogs were fasted or fed
...
....
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diets varying in fat concentration, the mean concentration of acid metabolite was still
>0.4 )lglml at 48 hours after administration oftepoxalin.
With the exception of defecation after administration of the IV dose of tepoxalin
no overt and significant adverse effects were observed. However, identification of
adverse effects was not included as an experimental objective of this study and
comprehensive physical or other examinations were not conducted after drug
administration.
A few data points were excluded from the pharmacokinetic analysis (see footnotes
to Tables 3 and 5) because the numbers did not correlate with the trend seen in the
individual animal. This was attributed to human error in handling the sample and
possible contamination of the sample with tepoxalin.
:
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TABLE 3 - Plasma concentrations of tepoxalin after oral administration of 10 mglkg to
fasted dogs and dogs fed a low fat meal. (Units in ug/ml)
PO/Fasted~
Time (m) #3308 #3309 #3310 #3311 #3312 #3313 Mean SD
0 <LOD <LOD <LOD <LOD <LOD <LaD
0.25 0.19 0.14 <LOQ - 0.13 0.14 0.15 0.02
0.5 0.13 0.31 0.35 <LOQ 0.16 0.21 0.23 0.09
1 0.27 0.55 0.65 <LaD 0.36 0.57 0.48 0.16
2 0.36 0.65 0.58 <LOQ 0.65 0.56 0.56 0.12
3 0.49 0.39 0.65 <LOQ 0.42 0.33 0.46 0.12
4 0.49 0.22 0.53 <LaD 0.28 0.25 0.36 0.14
6 0.26 0.19 0.34 <LOQ 0.13 0.17 0.22 0.08
8 0.20 0.21 0.32 <LOQ <LOQ 0.15 0.22 0.07
12 0.13 0.20 0.27 0.14 0.12 0.13 0.17 0.06
16 0.14 0.24 0.26 <LOQ <LOQ 0.30 0.24 0.07
24 <LOQ 0.21 0.32 <LaD <LOQ 0.12 0.22 0.10
32 0.16 <LaD 0.33 <LOQ <LOQ <LaD
48 0.15 <LOD 0.76* <LOQ <LOQ <LaD
POlLow
Fat~
Time (hr) #3308 #3309 #3310 #3311 #3312 #3313 Mean SD
0 <LaD <LaD <LaD <LaD <LaD <LaD
0.25 <LaD <LOQ 0.20 0.24 0.35 0.25 0.26 0.06
I 0.5 0.89 <LOQ 0.74 0.38 1.I3 0.53 0.74 0.29,
I 0.72 0.39 1.45 038 1.25 1.03 0.87 0.45
2 0.53 0.46 1.02 0.42 0.56 1.06 0.67 0.29
3 0.57 0.36 0.58 0.65 0.30 0.75 0.54 0.17
4 0.34 0.33 0.30 1.38 0.24 0.67 0.54 0.44
6 0.29 0.28 0.25 1.07 0.23 0.41 0.42 0.33
8 0.26 0.26 <LOD 0.61 <LaD 0.32 0.36 0.17
12 0.30 0.16 <LaD 0.39 <LOD 0.28 0.28 0.10
16 0.33 0.13 <LOD 0.12 <LaD 0.23 0.20 0.10
24 0.63* <LOD <LOD <LaD <LaD 0.23
32 0.34 <LOQ <LOD <LaD <LOQ 0.29
48 0.22 <LOQ <LaD <LaD <LOQ 0.23
... Data points excluded from pharmacokinetlc analyses.
:J
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TABLE 4 - Plasma concentrations of tepoxalin after oral administration of 10 mg/kg to
dogs fed a high fat meal and after intravenous administration. (Units in uglml)
PO/High
Fat:
Time (hr) #3308 #3309 #3310 #3311 #3312 #3313 Mean SO
0 <LaD <LaD <LaD <LaD <LaD <LaD
0.25 0.19 0.48 <LOQ <LOQ 0.25 <LOQ 0.31 0.16
0.5 0.87 0.30 <LOQ <LOQ 0.26 <LOQ 0,48 0.34
I 0.82 0.48 0.59 0.84 0.41 0.56 0.61 0.18
2 1.42 0.65 1.24 1.24 0.79 1.33 1.11 0.31
3 1.24 0.62 1.01 0.94 1.10 1.47 1.07 0.29
4 0.47 0.48 0.72 0.48 1.12 0.89 0.69 0.27
6 0.33 0.60 0.34 0.24 0.36 0.25 0.35 0.13
8 0.26 0.34 0.21 0.12 0.45 0.13 0.25 0.13
12 0.23 0.31 0.15 0.11 0.27 <LOQ 0.22 0.08
16 0.21 0.53 <LOQ <LaD 0.26 <LOO 0.34 0.17
24 0.22 0.34 <LOQ <LaD 0.31 <LaD 0.29 0.06
32 <LaD 0.44 <LOQ <LaD 0.57 <LaD
48 <LaD 0.30 <LOQ <LaD 0.50 <LaD
IV
Time (hr) #3308 #3309 #3310 #3311 #3312 #3313 Mean SO
0 <LaD <LaD <LaD <LaD <LaD <LaD
0.083 11.74 16.31 12.16 15.69 W.83 11.51 13.04 2.34
0.17 9.15 7.69 9.41 10.48 7.27 10.77 9.13 1.42
0.33 6.60 5.68 7.17 9.22 3.34 8.54 6.76 2.11
0.5 5.24 3.70 6.88 6.81 4.06 3.08 4.96 1.62
1 2.65 3.07 3.69 4.22 2.89 4.65 3.53 0.80
2 1.90 1.26 1.72 1.57 0.69 1.78 1.49 0.45
3 0.71 0.47 0.76 0.57 0.33 0.96 , 0.63 0.22
4 0.20 0.32 0.47 0.28 0.18 0.61 0.34 0.17
6 0.16 0.14 0.26 <LOQ <LOQ 0.33 0.22 0.09
8 0.24 <LOQ 0.24 <LOQ <LOQ 0.34 0.27 0.06
12 0.11 <LaD 0.22 <LOQ <LOQ 0.24 0.19 0.07
16 <LaD 0.14 0.19 <LOQ <LaD 0.22 0.18 0.04
24 <LaD <LaD <LaD <LOQ <LaD <LaD
32 <LaD <LaD <LaD <LOQ <LOQ <LaD
48 <LOD <LaD <LaD <LaD <LOQ <LaD
TABLE 5 - Plasma concentrations of acid metabolite after oral administration of 10
mglkg tepoxalin to fasted dogs and dogs fed a low fat meal. (Units in uglml)
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PO/Fasted:
Time (hr) #3308 #3309 #3310 #3311 #3312 #3313 Mean SD
0 <LaD <LaD <LaD <LaD <LaD <LaD
0.25 <LOQ <LOQ <LaD - <LOQ <LOQ
0.5 <LOQ 0.46 0.30 0.27 0.44 0.21 0.33 0.11
I 0.37 0.73 1.82 0.63 1.48 0.95 1.00 0.55
2 1.37 0.87 3.37 0.92 2.94 1.82 1.88 1.06
3 2.43 0.60 3.92 0.74 2.85 1.97 2.08 1.27
4 3.26 0.47 3.81 0.94 2.45 1.98 2.15 1.29
6 2.53 0.21 2.20 0.76 1.14 1.25 1.35 0.87
8 1.71 0.16 1.75 0.62 0.88 0.79 0.98 0.63
12 1.05 0.21 1.08 0.66 1.65 0.56 0.87 0.50 I
16 0.64 0.22 0.88 0.45 1.66 0.46 0.72 0.51
24 0.33 0.24 0.79 0.31 1.37 0.27 0.55 0.45
32 0.17 <LOD 0.43 0.26 0.94 <LOQ 0.45 0.34
48 0.23 <LaD 0.16 0.25 1.63* <LOQ 0.57 0.71
POlLow
Fat:
Time (hr) #3308 #3309 #3310 #3311 #3312 #3313 Mean SO
i 0 <LOD <LaD <LaD <LaD <LaD <LaD
0.25 0.15 <LOQ 0.55 0.28 0.32 0.39 0.33 0.15 ,
0.5 1.15 <LOQ 1.67 0.72 1.38 0.88 1.16 0.38
1 1.65 0.28 4.26 1.28 2.73 1.84 2.01 1.36
2 1.62 0.32 6.25 1.70 2.60 2.89 2.56 2.02
3 2.06 0.22 5.56 2.70 1.92 2.62 2.51 1.74
4 2.86 0.24 4.31 5.07 1.38 2.77 2.77 1.79
6 1.98 0.28 3.53 8.72 1.00 2.25 2.96 3.03
8 1.90 0.47 3.00 9.44 0.79 2.34 2.99 3.30
12 0.96 0.42 3.35 8.42 0.62 2.24 2.67 3.03
16 0.71 0.36 3.73 4.44 0.76 2.15 2.02 1.73
24 0.79 0.28 2.19 3.25 0.49 2.03 1.50 1.17
32 0.30 <LOQ 0.76 2.13 0.19 0.65 0.81 0.78
48 0.19 <LOQ 0.62 0.67 0.66 0.26 0.48 0.24
* Data point excluded from phannacokinetlc analySIS.
TABLE 6 - Plasma concentrations of acid metabolite after oral administration of 10
mglkg tepoxalin to dogs fed a high fat meal and after intravenous administration of
tepoxalin. (Units in uglml)
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POlHigh
Fat:
Time (hr) #3308 #3309 #3310 #3311 #3312 #3313 Mean SD
0 <LOD <LOD <LOD <LaD <LOD <LaD
0.25 <LOQ <LOQ <LOQ <LOQ <LOQ <LaD
0.5 0.46 0.14 <LOQ <LOQ <LOQ <LOQ
1 1.74 0.20 0.77 1.71 0.45 0.56 0.91 0.66
2 3.87 0.34 3.79 5.24 2.03 2.33 2.93 1.72
3 5.74 0.48 5.10 7.31 2.68 3.15 4.08 2.45
4 4.30 0.45 4.87 5.20 2.70 3.87 3.56 1.76
6 4.10 0.68 3.99 4.06 2.09 2.86 2.96 1.38
8 4.90 0.65 4.48 3.64 3.36 2.57 3.27 1.53
12 3.04 0.45 3.34 2.22 2.03 1.95 2.17 1.02
16 2.91 0.50 3.61 2.21 1.47 1.68 2.06 1.10
24 2.18 0.53 2.88 1.31 1.10 1.41 1.57 0.83
32 1.19 0.13 1.98 0.77 0.78 0.79 0.94 0.61
48 0.46 <LOQ 0.42 0.48 0.76 0.39 0.43 0.22
IV
Time (hr) #3308 #3309 #3310 #3311 #3312 #3313 Mean SD
0 <LOD <LaD <LOD <LOD <LaD <LaD
0.083 1.24 0.43 0.72 1.42 1.29 0.83 0.99 0.39
0.17 2.40 0.82 2.75 3.21 3.15 1.62 2.33 0.94
0.33 4.23 1.33 5.39 4.93 3.80 2.88 3.76 1.48
0.5 5.51 1.58 7.79 6.46 5.10 1.82 4.71 2.51
1 8.17 1.87 9.42 9.77 5.55 5.75 6.76 2.98
2 9.02 1.01 11.27 10.72 6.18 6.10 7.38 3.81
3 6.80 0.54 8.91 8.12 4.51 5.09 5.66 3.02
4 5.62 0.37 6.93 5.50 3.17 3.91 4.25 2.32
6 3.64 0.20 4.10 3.96 1.94 2.43 2.71 1.50
8 2.73 0.16 3.30 2.59 1.63 1.88 2.05 1.10
12 1.62 0.14 1.72 1.90 1.28 1.12 1.30 0.64 I
16 1.18 0.13 1.53 1.29 0.90 0.82 0.98 0.49
24 0.84 <LOQ 1.15 1.10 <LaD 0.78 0.97 0.18
32 0.40 <LOQ 1.03 0.42 0.71 0.20 0.55 0.32
48 0.19 <LOQ 0.64 0.23 0.97 <LOQ 0.51 0.37
~t
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TABLE 7 - Phannacokinetic parameters describing disposition of tepoxalin after oral or
intravenous administration (10 mg/kg).
PO/Fasted:
Value #3308 #3309 #3310 #3311 #3312 #3313 Mean SD
AVC (f.Lg·hr/ml) 7.48 6.86 10.80 1.09 2.59 5.88 5.78 3.51
AUMC 152.01 84.55 160.20 12.76 11.87 67.81 81.53 64.71
MRT(hr) 20.31 12.32 14.83 11.71 4.58 11.54 12.55 5.11
t JI2 (hr) 3190.71 18.99 30.28 - 4.43 13.39 651.56 1419.46
Cmax (I.lglml) 0.49 0.65 0.65 0.14 0.65 0.57 0.533 0.20
T max (hr) 3.50 2.00 1.00 12.00 2.00 1.00 3.58 4.22
F 62.67 56.98 70.08 7.89 32.71 35.85 44.36 23.22
PO/Low Fat:
Value #3308 #3309 #3310 #33 II #3312 #3313 Mean SD
AVC (I.lKhr/ml) 17.90 4.37 3.97 9.88 3.13 15.29 9.09 6.34
AUMC 397.32 34.03 9.82 69.16 7.39 301.24 136.49 169.07
MRT(hr) 22.19 7.79 2.48 7.00 2.36 19.70 10.25 8.62
tl/2 (hr) 57.97 8.01 1.84 6.07 2.13 23.49 16.59 21.78
Cmax (I.lglml) 0.89 0.46 1.45 1.38 1.25 1.06 1.08b 0.37
Tmax (hr) 0.50 2.00 1.00 4.00 1.00 2.00 1.75 1.25
F 149.93 36.26 25.72 71.54 39.48 93.26 69.36 46.82
PO/High Fat:
Value #3308 #3309 #3310 #3311 #3312 #3313 Mean SO
AUC (I.lg·hr/ml) 9.73 19.62 5.68 4.81 22.07 5.45 11.23 7.69
AUMC 93.81 437.05 26.59 19.85 535.41 18.95 188.61 234.30
MRT (hr) 9.64 22.27 4.68 4.13 24.26 3.48 11.41 9.46
tll2(hr) 8.97 79.12 3.24 2.69 65.57 2.36 26.99 35.47
Cmax (I.lglml) 1.42 0.65 1.24 1.24 1.12 1.47 1.19 b 0.29
T max (hr) 2.00 2.00 2.00 2.00 4.00 3.00 2.50 0.84
F 81.51 162.90 36.86 34.84 278.43 33.22 104.62 98.69
IV:
Value #3308 #3309 #3310 #3311 #3312 #3313 Mean SO
AUC (I.lg·hr/ml) 11.94 12.05 15.42 13.81 7.93 16.39 12.92 3.02
AUMC 23.59 24.48 50.81 11.67 6.71 59.64 29.48 21.26
MRT (hr) 1.98 2.03 3.30 0.85 0.85 3.64 2.11 1.18
tl/2(hr) 2.17 3.14 4.11 0.73 0.78 3.76 2.45 1.47
a,b Means with different superscripts are significantly different.
~I
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TABLE 8 - Phannacokinetic parameters describing disposition of the acid metabolite of
tepoxalin after administration of tepoxalin (10 mglkg).
PO/Fasted:
Value #3308 #3309 #3310 #3311 #3312 #3313 Mean SO
AUC (J.1g·hr/ml) 33.72 7.88 46.49 19.96 37.70 19.07 27.47 14.26
AUMC 430.07 90.63 625.74 364.46 435.20 178.36 354.08 193.15
MRT(hr) 12.76 1l.51 13.46 18.26 11.54 9.35 12.81 3.01
t1/2 (hr) 10.47 12.78 10.32 21.86 26.27 7.21 14.82 7.51
Cmax (J.1g/ml) 3.26 0.87 3.92 0.94 2.94 1.98 2.32 1.26
Tmax (hr) 4.00 2.00 3.00 4.00 2.00 4.00 3.17 0.98
POlLow Fat:
Value #3308 #3309 #3310 #3311 #3312 #3313 Mean SO
AUC (J.1g·hr/ml) 38.88 9.16 105.67 176.31 32.13 70.97 72.19 61.07
AUMC 551.48 126.07 1642.22 2903.83 575.73 1168.11 1161.24 1005.41
MRT(hr) 14.19 13.76 15.54 16.47 17.92 16.46 15.72 1.56
till (hr) 11.65 22.06 14.05 10.60 18.31 14.15 15.14 4.31
Cmax (J.1g/ml) 2.86 0.47 6.25 9.44 2.73 2.89 4.11 3.20
Tmax (hr) 4.00 8.0f) 2.00 8.00 1.00 2.00 4.17 3.13
POlHigh Fat:
Value #3308 #3309 #3310 #3311 #3312 #3313 Mean SD
-._.
AVC (J.lg·hr/ml) 105.46 16.25 123.37 86.37 64.54 66.90 77.15 .P.41
AUMC 1696.39 280.76 132.03 1251.21 1175.48 1112.47 941.39 606.89
MRT(hr) 16.09 17.28 107 14.49 18.21 16.63 13.96 6.44
tIll (hr) 13.21 9.65 14.29 11.97 20.70 14.23 ]4.01 3.71
Cmax (J.1g/ml) 5.74 0.68 5.10 7.31 2.70 3.87 4.23 2.35
Tmax (hr) 3.00 6.00 3.00 3.00 4.00 4.00 3.83 1.17
IV:
Value #3308 #3309 #3310 #3311 #3312 #3313 Mean SD
AVC (J.1g-hr/ml) 75.39 6.61 102.38 84.62 58.01 51.26 63.05 33.21
AUMC 767.58 33.06 1319.50 873.08 905.57 489.06 731.31 434.51
MRT(hr) 10.18 5.00 12.89 10.32 15.61 9.54 10.59 3.55
t 1!2 (hr) 8.31 3.88 1123 8.46 16.71 6.83 9.24 4.37
Cmax (J.1g/ml) 9.02 187 11.27 10.72 6.18 6.10 7.53 3.53
Tmax (hr) 2.00 100 2.00 2.00 2.00 2.00 1.83 0.41
]0
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Figure 2 - Mean tepoxalin concentrations after intravenous (IV) or oral (PO)
administration to fasted (FAST) dogs or dogs fed low fat (Lfat) or high fat
(Hfat) diets (n = 6)
10
34
--<>-- POlFast
-0- POlLfat
-i:r- PO/Hfat
• \y
o 16 24 32 40 48
Time after administration (hours)
Figure 3 - Mean tepoxalin acid metabolite concentrations after intravenous (IV) or oral
(PO) administration to fasted (FAST) dogs or dogs fed low fat (Lfat) or
high fat (Hfat) diets (n = 6)
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CHAPTER VI
DISCUSSION & CO CLUSIONS
Although it is widely known that corticosteroids and NSAIDs can help alleviate
the symptoms of canine osteoarthritis, both groups of drugs have undesirable side effects.
Researchers are continually looking for new drugs that can control the inflammatory
process of osteoarthritis with fewer adverse side effects. Tepoxalin appears to be one
such discovery. This study was conducted to describe the phannacokinetics of tepoxalin
both orally and intravenously and to investigate absorption rates of the drug when the fat
content of the diet was varied.
When given intravenously, it was noted that the parent drug, tepoxalin, was
rapidly metabolized and formed an acid metabolite. Tepoxalin undergoes a first-pass
effect through the liver and this accounts for the rapid decrease in tepoxalin in plasma
while the acid metabolite concentration increases and remains higher than the
concentration of the parent drug over the 48 hour sampling period. This same pattern can
be seen when the fat content of the diet is varied at the time of oral drug administration.
The oral bioavailability oftepoxalin is also affected by the diet at the time of drug
administration. Several studies have looked at the effects of diet and drug bioavailability.
Some of the factors considered are gastric motility and the physical interaction of the food
with the drug (Toothaker, et aI, 1980).
When food is ingested, it delays gastric emptying due to feedback mechanisms of
certain chemical receptors in the small intestine (Toothaker, et aI, 1980). Also, many
36
drugs are absorbed in the small intestine and a delay in stomach emptying leads to a delay
in reaching the small intestine and the optimal site of absorption (Toothaker, et ai, 1980).
The food itself may act as a physical barrier preventing the drug from being absorbed
from the mucosal surface or it could complex with the drug (Toothaker, et ai, 1980).
Food intake is known to decrease the oral bioavailability of tetracycline, penicillin V,
penicillin G, cephalexin, erythromycin stearate, and aspirin (Toothaker, et ai, 1980).
Tepoxalin was administered in a rapid-dissolution fonn to the dogs, which
allowed for a faster absorption from the mucosal surface of the stomach. The structure of
tepoxalin, as noted by Tam, et ai, is composed of a pyrazole group and a hydroxamic acid
group (1995). These groups give tepoxalin the ability to be lipid soluble and thus easily
pass through the phospholipid bilayer of the cell membrane. The results of the research
suggest that the fat in the diet allows the drug to more easily cross the GIT mucosal
barrier and thus be more effective. Although a fatty diet contains micelles and some
drugs may extend their efficacy by being transported in them resulting in protection from
metabolic enzymes, this appears not to be the case with tepoxalin. As mentioned
previously, the active acid metabolite is fonned within 8 hours and for this to occur, the
hepatic enzymes need to have access to the parent drug to break it down and fonn the
metabolite.
In conclusion, this study has shown that diet has an affect on the oral
bioavailability of tepoxalin and the phannacokinetic parameters calculated have
demonstrated that aspect. The ability to administer the drug orally, the increased half-life
demonstrated by the drug, and the few adverse side effects make tepoxalin a good
candidate as an anti-inflammatory agent in the treatment of osteoarthritis in dogs. Further
37
research needs to be done on the acid metabolite of tepoxalin to detennine its role in the
prevention of inflammation.
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